Dr Nabil Kaddis Bissada, MD in Oklahoma City, OK - Urology

Dr Nabil Kaddis Bissada, MD is a Urology physician based in Oklahoma City, Oklahoma. Dr Nabil Kaddis Bissada is licensed to practice in Oklahoma (license number 29007) and his current practice location is 825 N.e. 10th Street, Suite 5400, Oklahoma City, Oklahoma. He can be reached at his office (for appointments etc.) via phone at (405) 271-6452.

NPI number for Dr Nabil Kaddis Bissada is 1932299500 and his current mailing address is 920 Stanton L. Young Boulevard, Wp3150, Oklahoma City, Oklahoma. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1932299500.

Contact Information

	Dr Nabil Kaddis Bissada, MD
	825 N.e. 10th Street, Suite 5400, Oklahoma City, OK 73104
	(405) 271-6452
	Not Available

Physician's Profile

Full Name	Dr Nabil Kaddis Bissada
Gender	Male
Speciality	Urology
Location	825 N.e. 10th Street, Oklahoma City, Oklahoma
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1932299500
Provider Enumeration Date: 10/13/2006
Last Update Date: 06/13/2013

Medical Identifiers

Medical identifiers for Dr Nabil Kaddis Bissada such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1932299500	NPI	-	NPPES
148787001	Medicaid	AR

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208800000X	Urology	R-2121 (Arkansas)	Secondary
208800000X	Urology	29007 (Oklahoma)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Nabil Kaddis Bissada is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Nabil Kaddis Bissada, MD 920 Stanton L. Young Boulevard, Wp3150, Oklahoma City, OK 73104 Ph: (405) 271-6900	Dr Nabil Kaddis Bissada, MD 825 N.e. 10th Street, Suite 5400, Oklahoma City, OK 73104 Ph: (405) 271-6452

News Archive

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine's efficacy in treating asthma patients and is not currently approved for this indication.

Ecstasy and speed-using grade ten students more likely to develop depression

A five year study conducted with thousands of local teenagers by University of Montreal researchers reveals that those who used speed (meth/ampthetamine) or ecstasy (MDMA) at fifteen or sixteen years of age were significantly more likely to suffer elevated depressive symptoms the following year. "Our findings are consistent with other human and animal studies that suggest long-term negative influences of synthetic drug use," said co-author Fr-d-ric N. Bri-re of the School Environment Research Group at the University of Montreal.

Biostar receives Shaanxi SFDA approval to market Xin Aoxing Oleanolic Acid Capsules

Biostar Pharmaceuticals, Inc., the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsule, and other pharmaceutical products, announced today it has received new advertising approval from Shaanxi State Food and Drug Administration for marketing Xin Aoxing Oleanolic Acid Capsules.

Laserscope issued new U.S. patent

Laserscope announced today that it has been issued an important U.S. patent from the United States Patent and Trademark Office (USPTO) relating to the use of its Photoselective Vaporization (PV) method and technology for therapeutic treatment of benign prostatic hyperplasia (BPH) and other tissues in the human body.

Urology Doctors in Oklahoma City, OK

Dr. Jeremy Alex Davis, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 13509 N Meridian Ave Ste 6, Oklahoma City, OK 73120 Phone: 405-768-1180 Fax: 405-768-1181
Barbara L Voss-alvarez, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 11000 Hefner Pointe Dr, Oklahoma City, OK 73120 Phone: 405-749-9655 Fax: 405-749-1001
Rajendra K. Motwani, DO Urology Medicare: Accepting Medicare Assignments Practice Location: 9817 S Western Ave, Oklahoma City, OK 73139 Phone: 405-632-4500 Fax: 405-632-7500
Richard E Herlihy, MD Urology Medicare: May Accept Medicare Assignments Practice Location: 4140 W Memorial Rd, Suite 611, Oklahoma City, OK 73120 Phone: 405-749-4288 Fax: 405-749-4287
Daniel J Culkin, MD Urology Medicare: Medicare Enrolled Practice Location: 825 Ne 10th St, Oupb5400, Oklahoma City, OK 73104 Phone: 405-271-6452
Dr. Brian Alan Link, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 4140 W Memorial Rd, Suite 518, Oklahoma City, OK 73120 Phone: 405-749-4230 Fax: 405-749-4228
Amber Bauer, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 920 Stanton L Young Blvd # Wp3150, Oklahoma City, OK 73104 Phone: 405-271-6900

Dr Nabil Kaddis Bissada, MD - Urology in Oklahoma City, OK